Supha Pharmachem Enters Insolvency: NCLT Admits CIRP Over ₹7.47 Cr Debt

Supha Pharmachem Limited, previously known as Remedium Lifecare Limited, has been admitted into the Corporate Insolvency Resolution Process (CIRP) by the Mumbai bench of the National Company Law Tribunal (NCLT). The company faces a debt default of ₹7.47 crore, resulting in a moratorium and the suspension of its board.

Key Developments

The NCLT Mumbai Bench pronounced its order on March 17, 2026, admitting the petition filed by Boston Ivy Healthcare Solution Private Limited. The insolvency proceedings were initiated due to an outstanding operational debt of ₹7.47 crore, comprising ₹6.19 crore in principal dues and ₹1.28 crore in interest.

The tribunal declared a moratorium under Section 14 of the Insolvency and Bankruptcy Code (IBC), 2016, effectively halting all legal actions, asset transfers, and recovery proceedings against the company.

Management of the corporate debtor has now vested with the appointed Interim Resolution Professional (IRP), Mr. Rajesh Jhunjhunwala, with an initial cost deposit of ₹3 lakh.

The company, previously known as Remedium Lifecare Limited, officially changed its name to Supha Pharmachem Limited on December 15, 2025.

Why this matters

Admission into CIRP signals significant financial distress for Supha Pharmachem. The moratorium freezes the company's operations and assets, preventing creditors from taking immediate action but also halting business continuity. Management control now rests with the Interim Resolution Professional (IRP), tasked with managing the company and finding a resolution plan, which could lead to revival, sale, or liquidation.

Company Background

Supha Pharmachem Limited, formerly Remedium Lifecare Limited, has a history of corporate restructuring and financial difficulties. The company changed its name from Roxy Exports Limited in 2020. In recent years, it drew scrutiny from the Securities and Exchange Board of India (SEBI) over its financial reporting and investor communications. A notable controversy involved incorrect news reports about a supposed ₹8,500 crore order from Eli Lilly, which the company later denied as speculative. Frequent board resignations have also raised governance concerns. Despite efforts at diversification and business expansion, including a rights issue in April-May 2025, the company's financial health has remained fragile, with its stock price declining significantly.

What changes now

Management Control: The existing board of directors' powers are suspended. Day-to-day management is now handled by the IRP.
Asset Protection: A moratorium prevents creditors from suing the company, seizing assets, or pursuing recovery actions.
Operational Continuity: Suppliers of essential goods and services are required to maintain their supply during the moratorium period.
Creditor Claims: All creditors must submit their claims to the IRP by March 31, 2026.
Resolution Process: The IRP will work to find a resolution plan, which may involve restructuring, selling assets, or liquidation.
Shareholder Value: The company's equity value faces significant risk, with potential dilution or complete loss if liquidation occurs.

Risks to watch

Resolution Uncertainty: The main risk is the unpredictable outcome of the resolution process, potentially leading to liquidation if no viable plan is approved.
Debt Burden: The ₹7.47 crore operational debt is the direct cause of the insolvency filing.
Regulatory Scrutiny: Past regulatory concerns from SEBI regarding financial disclosures might re-emerge.
Governance Issues: Concerns about board stability and previous transparency issues could hinder resolution efforts.
Market Sentiment: Negative investor sentiment and the risk of delisting are also key concerns.

Peer comparison

Supha Pharmachem (formerly Remedium Lifecare) entering insolvency proceedings contrasts sharply with larger peers such as Torrent Pharmaceuticals, Sun Pharmaceutical Industries, and Dr. Reddy's Laboratories. These established companies benefit from strong financial health, broad market reach, and solid governance, positioning them for growth. Supha Pharmachem's admission to CIRP, however, marks a severe financial crisis, a situation uncommon among its well-capitalized competitors.

Key Metrics

Date of Default: The default event triggering the insolvency claim occurred on November 7, 2023.
IRP Cost Deposit: An initial ₹3,00,000 has been deposited for the Interim Resolution Professional's costs.

What to track next

IRP Announcement: The IRP is expected to issue a formal public announcement about the CIRP commencement.
Creditor Claims: Watch for the total debt amount as creditors submit their claims.
Resolution Plan: Monitor the IRP's progress in forming a creditors' committee and seeking a resolution plan.
Company's Future: Future developments will show if the company can be revived or faces liquidation.